Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New York, US, and Suzhou, China, announced the first patient dosing in a Phase Ib study. The study is designed to assess the safety and efficacy of its RIPK2 inhibitor AC-101 in moderate to severe ulcerative colitis (UC).
Drug Background
AC-101 is derived from Accropeutics’ “regulatory cell death and inflammation”-targeted R & D platform. It has demonstrated significant protective effects in multiple animal models of inflammatory bowel diseases. The drug previously obtained FDA clearance for a multi-regional Phase II study in UC.
Study Details
The Phase Ib study will evaluate the safety and efficacy of AC-101 in patients with moderate to severe UC. This marks a key milestone in the development of the drug, which has shown promise in preclinical studies.-Fineline Info & Tech
